Between January, 1975, and December, 1978, 118 patients with advanced Hodgkin's disease were treated with 8 months of alternating MOPP and adriamycin, bleomycin, dacarbazine and vinblastine (ABDV) combined with 1 month of low-dose radiation therapy (2,000 rad) to areas initially involved with bulky
S 4.4 - Advances in Treatment of Autoimmune Diseases
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- English
- Weight
- 83 KB
- Volume
- 39
- Category
- Article
- ISSN
- 0014-2980
No coin nor oath required. For personal study only.
โฆ Synopsis
Abstract
No Abtract
๐ SIMILAR VOLUMES
In 35 cases of advanced Hodgkin's disease (stage IIIB to IVB), of whom 33 were no longer responsive to the alkylating agents, vinblastine produced clinically useful remissions in 22 patients or 64%. Complete objective responses were unusual but one third of these cases experienced partial remissions
There are two main approaches to the treatment of Alzheimer's disease. The ยฎrst approach is to prevent the neurodegenerative changes that ultimately cause irreversible damage to the brain. As the excessive formation of betaamyloid protein appears to play a primary role in the neurodegenerative proce
he in vivo local delivery of regulatory cytokines made possible by gene therapy is becoming an exciting approach for treating common disorders such as cancer and viral infections I. Recently, gene therapy strategies have been applied to the treatment of autoimmune diseases. Cells targeted for autoim
## Abstract Autoimmune diseases are characterized by the loss of tolerance toward selfโantigens and the induction of destructive immune responses leading to tissue damage. Most patients with autoimmune diseases are treated with immunosuppressive drugs that suppress the immune response in a nonโspec